3 results
Primary: to assess the effect of intravenous (IV) ozanezumab (15 mg/kg once every 2 weeks) compared to placebo on the physical function and survival of ALS patients over a treatment period of 48-weeks.Secondary (major): other clinical outcomes,…
Aim of this study is to determine the effectiveness of ESWT on pain, symptoms and function, in athletes with patellar tendinopathy (in an early stage of the disease) who are still able to train and compete.
The goal of this study is to examine the effect of both treatment strategies on the running distance of the Cooper*s test, a part of the Defensie Conditie Proef (DCP) and on the time of a 5k march, as these are important indicators whether the…